幽门螺杆菌口服疫苗体系优选OA
Optimization of Oral Vaccine System for Helicobacter Pylori
目的 优化幽门螺杆菌(H.pylori)口服疫苗体系.方法 制备 H.pylori 黏附素 A(HpaA)和尿素酶 B 亚基(UreB)抗原;将 SPF 级雌性 BALB/c 小鼠随机分为阴性对照组(等体积生理盐水,下同)、抗原组(UreB+HpaA,UreB 为 500 μg/只,HpaA 为 500 μg/只,下同)、A 组[UreB+HpaA+LT(B)5,LT(B)5 为 125 μg/只]、B 组(UreB+HpaA+CpG1018,CpG1018 为 50 μg/只,下同)、C 组(UreB+HpaA+壳聚糖,壳聚糖为 1 600 μg/只)、D 组(UreB+HpaA+CpG1018+癸酸钠组,癸酸钠为 4 mg/只)、E 组(UreB+HpaA+CpG1018+SNAC,SNAC 为 4mg/只)、F 组(UreB+HpaA+CpG1018+脱氧胆酸钠,脱氧胆酸钠为 4mg/只),各 7 只;将 40 只 SPF BALB/c 小鼠,随机分为阴性对照组,模拟疫苗对照组(CpG1018+脱氧胆酸钠),低剂量组(F 组 400 μL/只)和高剂量组(F 组800 μL/只),各 10 只,雌雄各半,分别于第 0,7,14,21 天免疫小鼠,按相应剂量灌胃,每次 400 μL(800 μL 分 2 次灌胃).采用酶联免疫吸附试验(ELISA)法测定抗原组和 A-F 组小鼠血清免疫球蛋白 G(IgG)和肠道灌洗液分泌型免疫球蛋白 A(sIgA)水平;采用平板法检测阴性对照组、抗原组及 A-F 组小鼠胃组织 H.pylori 定植量;记录阴性对照组、模拟疫苗对照组、低剂量组及高剂量组小鼠死亡率、体质量、耗食量,并采用苏木精-伊红(HE)染色法观察阴性对照组和低剂量组小鼠各器官组织病理形态.结果 重组质粒pET29b-HpaA/UreB 体系经双酶切验证构建成功,纯化后 3 批抗原样品纯度最低可达 91.0%(HpaA)和 91.9%(UreB).F 组小鼠抗UreB 特异性血清 IgG、肠道 sIgA 水平及抗 HpaA 特异性肠道 sIgA 水平均显著高于 B 组、D 组和 E 组(P<0.05),抗 HpaA 特异性血清IgG 水平显著高于 B 组(P<0.001);与阴性对照组比较,F 组小鼠胃组织 H.pylori 定植量显著降低(P<0.05).与阴性对照组比较,模拟疫苗对照组、低剂量组和高剂量组小鼠死亡率、体质量及耗食量均无显著变化,且低剂量组小鼠心脏、肝脏、脾脏、肺、肾脏、胃和小肠组织均未显示出明显的系统毒性和给药部位的局部刺激性病理形态.结论 所优化的 CpG1018 佐剂-脱氧胆酸钠口服吸收促进剂辅助 HpaA-UreB 抗原口服疫苗体系,可显著增强小鼠的系统免疫应答,降低 H.pylori 定植量,且具有一定安全性.
Objective To optimize the oral vaccine system of Helicobacter pylori(H.pylori).Methods H.pylori adhesin A(HpaA)and urease B subunit(UreB)antigens were prepared.SPF female BALB/c mice were randomly divided into the negative control group(equal volume of normal saline,the same below),antigen group(UreB+HpaA,UreB was 500 μg/mouse,HpaA was 500 μg/mouse),group A[UreB+HpaA+LT(B)5,LT(B)5 was 125 μg/mouse],group B(UreB+HpaA+CpG1018,CpG1018 was 50 μg/mouse,the same below),group C(UreB+HpaA+chitosan,chitosan was 1 600 μg/mouse),group D(UreB+HpaA+CpG1018+sodium decanoate,sodium decanoate was 4 mg/mouse),group E(UreB+HpaA+CpG1018+SNAC,SNAC was 4 mg/mouse),group F(UreB+HpaA+CpG1018+sodium deoxycholate,sodium deoxycholate was 4 mg/mouse),with seven mice in each group,a total of 40 SPF BALB/c mice were randomly divided into the negative control group,simulated vaccine control group(CpG1018+sodium deoxycholate),low-dose group(group F,400 μL/mouse)and high-dose group(group F,800 μL/mouse),with 10 mice in each group,half male and half female,respectively.The mice were immunized on day 0,7,14 and 21,were administered the corresponding dose by gavage,400 μL each time(800 μL in two administrations).Enzyme-linked immunosorbent assay(ELISA)method was used to determine the levels of serum immunoglobulin G(IgG)and intestinal lavage fluid secretory immunoglobulin A(sIgA)of the antigen group and group A-F in mice;the plate method was used to detect the amount of H.pylori colonization in gastric tissue in the negative control group,antigen group and group A-F of mice;mortality,body weight and food consumption in the negative control group,simulated vaccine control group,low-dose group and high-dose group of mice were recorded,and hematoxylin-eosin(HE)staining method was used to observe the pathological morphology of organs and tissues in the negative control group and low-dose group of mice.Results The recombinant plasmid pET29b-HpaA/UreB system was successfully constructed by double enzyme digestion.After purification,the purity of the three batches of antigen samples was at least 91.0%(HpaA)and 91.9%(UreB).The levels of anti UreB specific serum IgG,intestinal sIgA and anti HpaA specific intestinal sIgA in the group F were significantly higher than those in the group B,D and E(P<0.05),and the level of anti HpaA specific serum IgG was significantly higher than that in the group B(P<0.001);compared with the negative control group,the colonization of H.pylori in gastric tissue of mice in the group F was significantly decreased(P<0.05).Compared with the negative control group,the mortality,body weight and food consumption of mice in the simulated vaccine control group,low-dose group and high-dose group were not significantly changed,and the heart,liver,spleen,lung,kidney,stomach and small intestine of mice did not show obvious systemic toxicity and local irritant pathological morphology at the administration site in the low-dose group.Conclusion The optimized CpG1018 adjuvant-sodium deoxycholate oral absorption enhancer assisted HpaA-UreB antigen oral vaccine system can significantly enhance the systemic immune response in mice,reduce the colonization of H.pylori,and is relatively safety.
陈正军;樊钒;吴强;陈克平;董重;李建霖;陈传凤;樊绍文
成都欧林生物科技股份有限公司,四川 成都 611730成都欧林生物科技股份有限公司,四川 成都 611730成都欧林生物科技股份有限公司,四川 成都 611730成都欧林生物科技股份有限公司,四川 成都 611730成都欧林生物科技股份有限公司,四川 成都 611730成都欧林生物科技股份有限公司,四川 成都 611730成都欧林生物科技股份有限公司,四川 成都 611730成都欧林生物科技股份有限公司,四川 成都 611730
医药卫生
幽门螺杆菌疫苗口服吸收促进剂脱氧胆酸钠尿酶素幽门螺杆菌黏附素A
Helicobacter pylorivaccinesabsorption enhancersodium deoxycholate
《中国药业》 2026 (10)
46-52,7
四川省科技计划项目[2024YFFK0020].
评论